314 related articles for article (PubMed ID: 27875388)
1. Is vulvovaginal atrophy due to a lack of both estrogens and androgens?
Labrie F; Martel C; Pelletier G
Menopause; 2017 Apr; 24(4):452-461. PubMed ID: 27875388
[TBL] [Abstract][Full Text] [Related]
2. Science of intracrinology in postmenopausal women.
Labrie F; Bélanger A; Pelletier G; Martel C; Archer DF; Utian WH
Menopause; 2017 Jun; 24(6):702-712. PubMed ID: 28098598
[TBL] [Abstract][Full Text] [Related]
3. Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina.
Berger L; El-Alfy M; Martel C; Labrie F
J Steroid Biochem Mol Biol; 2005 Jul; 96(2):201-15. PubMed ID: 15979306
[TBL] [Abstract][Full Text] [Related]
4. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
[TBL] [Abstract][Full Text] [Related]
5. Androgenic action of dehydroepiandrosterone (DHEA) on nerve density in the ovariectomized rat vagina.
Pelletier G; Ouellet J; Martel C; Labrie F
J Sex Med; 2013 Aug; 10(8):1908-14. PubMed ID: 23782654
[TBL] [Abstract][Full Text] [Related]
6. Localization of the androgen-synthesizing enzymes, androgen receptor, and sex steroids in the vagina: possible implications for the treatment of postmenopausal sexual dysfunction.
Bertin J; Dury AY; Ouellet J; Pelletier G; Labrie F
J Sex Med; 2014 Aug; 11(8):1949-61. PubMed ID: 24919541
[TBL] [Abstract][Full Text] [Related]
7. Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat.
Sourla A; Flamand M; Bélanger A; Labrie F
J Steroid Biochem Mol Biol; 1998 Aug; 66(3):137-49. PubMed ID: 9719448
[TBL] [Abstract][Full Text] [Related]
8. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
Wang J; Wang L
Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
[TBL] [Abstract][Full Text] [Related]
10. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women.
Labrie F; Diamond P; Cusan L; Gomez JL; Bélanger A; Candas B
J Clin Endocrinol Metab; 1997 Oct; 82(10):3498-505. PubMed ID: 9329392
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women.
Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):178-94. PubMed ID: 18598765
[TBL] [Abstract][Full Text] [Related]
12. Intracrinology and the skin.
Labrie F; Luu-The V; Labrie C; Pelletier G; El-Alfy M
Horm Res; 2000; 54(5-6):218-29. PubMed ID: 11595810
[TBL] [Abstract][Full Text] [Related]
13. All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.
Labrie F
J Steroid Biochem Mol Biol; 2015 Jan; 145():133-8. PubMed ID: 24923731
[TBL] [Abstract][Full Text] [Related]
14. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology.
Labrie F; Luu-The V; Labrie C; Simard J
Front Neuroendocrinol; 2001 Jul; 22(3):185-212. PubMed ID: 11456468
[TBL] [Abstract][Full Text] [Related]
15. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
Holton M; Thorne C; Goldstein AT
Expert Opin Pharmacother; 2020 Mar; 21(4):409-415. PubMed ID: 31928093
[No Abstract] [Full Text] [Related]
16. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women.
Portman DJ; Labrie F; Archer DF; Bouchard C; Cusan L; Girard G; Ayotte N; Koltun W; Blouin F; Young D; Wade A; Martel C; Dubé R;
Menopause; 2015 Dec; 22(12):1289-95. PubMed ID: 25968836
[TBL] [Abstract][Full Text] [Related]
17. Prasterone: A Review in Vulvovaginal Atrophy.
Heo YA
Drugs Aging; 2019 Aug; 36(8):781-788. PubMed ID: 31290076
[TBL] [Abstract][Full Text] [Related]
18. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
Panjari M; Davis SR
Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
[TBL] [Abstract][Full Text] [Related]
19. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone.
Labrie F; Luu-The V; Labrie C; Bélanger A; Simard J; Lin SX; Pelletier G
Endocr Rev; 2003 Apr; 24(2):152-82. PubMed ID: 12700178
[TBL] [Abstract][Full Text] [Related]
20. Effects of ovariectomy and dehydroepiandrosterone (DHEA) on vaginal wall thickness and innervation.
Pelletier G; Ouellet J; Martel C; Labrie F
J Sex Med; 2012 Oct; 9(10):2525-33. PubMed ID: 22905785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
